Sparian Biosciences
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
180 Varick St Ste 615, New York, New Yor...Website
www.sparianbiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Sparian Biosciences
Sparian Biosciences is a clinical stage bio-pharmaceutical company dedicated to discovering and developing innovative therapies aimed at treating conditions related to the central nervous system (CNS). The company focuses on novel CNS drugs, positioning itself within the biopharmaceutical industry. Its intended clients include healthcare providers and patients seeking advanced treatment options for CNS disorders. Sparian Biosciences is committed to advancing medical science through its research and development efforts.Explore more
Sparian Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sparian Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Sparian Biosciences had a recent Job posting/layoffs
Sparian Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Sparian Biosciences has new funding data
Product Launch: Get notified when Sparian Biosciences launches new products
Check if Sparian Biosciences has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sparian Biosciences
Earning: See what the market has to say on Sparian Biosciences recently announced quarterly report
Check out if Sparian Biosciences is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Sparian Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Sparian Biosciences
Compare insights from companies similar to Sparian Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sparian Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sparian Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sparian Biosciences.
Sparian Biosciences Tech Stack
A closer look at the technologies used by Sparian Biosciences
Sparian Biosciences News & Media
Sparian Biosciences Awarded $19.5 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/ Opiate Withdrawal Syndrome Through Phase 1 Clinical Development
Sparian Biosciences announced that it has been awarded a $19.5 million, five-year grant to fund development of SBS-226Sparian Biosciences Announces Formation of its Science Advisory Board
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board (SAB) with the appointments of Eric Nestler, M.D./PhD, Frances Levin M.D. and Nathaniel Katz, M.D. The SAB was established around clear areas of expertise related to Sparian’s therapeutic focus on pain and substance use disorders.Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
Sparian Biosciences announced results from the Phase 1 clinical trial of the first in class novel AEAr agonist analgesic SBS-1000.Sparian Biosciences Awarded Five-Year NIH/NDA Grant for Development of SBS-518
SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sparian Biosciences
Sign Up For FreeTo access detailed company insights
Sparian Biosciences is a clinical stage bio-pharmaceutical company dedicated to discovering and developing innovative therapies aimed at treating conditions related to the central nervous system (CNS). The company focuses on novel CNS drugs, positioning itself within the biopharmaceutical industry. Its intended clients include healthcare providers... Read More
